- Category
- Announcements
- Date
- Feb. 17, 2010
- Title
-
Kramer Levin Client Kroll Inc. Sells Kroll Laboratory Specialists to Inverness Medical Innovations
On February 17, Inverness Medical Innovations, Inc. completed its acquisition of Kroll Laboratory Specialists, Inc. - the Substance Abuse Testing Division of Kramer Levin client Kroll Inc., which is a subsidiary of Marsh and McLennan Companies. Inverness had entered into a binding agreement with Kroll to purchase Kroll Laboratory Specialists, its business unit providing forensic quality substance abuse testing products and services across the United States, on February 3. The purchase price was $110 million cash subject to a customary working capital adjustment.
Inverness Medical Innovations, Inc. is a global developer of advanced medical diagnostic products and a leader in specialized health management.
The Kramer Levin team was led by Corporate partner Peter S. Kolevzon and associates Michael Brooks, Kelly Rau and Stephanie N. Restifo. They were assisted by Tax partner Barry Herzog and associate Blade A. Rigel, Employee Benefits and Executive Compensation partner Christine Lutgens and special counsel Avram J. Cahn and Intellectual Property partner Kevin M. Moss.
The Deal Pipeline and HealthLaw 360 originally reported on the transaction.
Related People
-
-
Barry Herzog
-
- Partner
- Chair, Tax
- New York
- vcard
-
-
-
Avram J. Cahn
-
- Special Counsel
- New York
- vcard
-
-
-
Kevin M. Moss
-
- Counsel
- New York
- vcard
-
